No Data
Unigroup Guoxin (301166.SZ): cumulative repurchased 0.49% of shares.
Grant Hui Nov. 1st | Yuninwei (301166.SZ) announced that as of October 31, 2024, the company repurchased a total of 421,700 shares of the company through a special securities account for share repurchases in a centralized auction trading manner, accounting for 0.49% of the total share capital of the company. The highest fill price was 30 yuan/share, and the lowest fill price was 24.98 yuan/share, with a total amount paid of 11,369,227 yuan (excluding transaction costs). The repurchase of shares this time is in compliance with relevant laws, administrative regulations, normative documents, and company share repurchase schemes.
Unionway: 2024 Third Quarter Report
Youniwei (301166.SZ): The net income in the first three quarters was 14.0791 million yuan, a year-on-year decrease of 65.05%.
On October 28, Yuninwei (301166.SZ) announced its third quarter report for 2024, with the company achieving revenue of 0.828 billion yuan for the first three quarters, a 6.60% year-on-year decrease; net income attributable to shareholders of the listed company was 14.0791 million yuan, a 65.05% year-on-year decrease; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was -4.0169 million yuan; and basic earnings per share was 0.16 yuan.
You Ningwei (301166.SZ) released its performance for the first three quarters, with a net income of 14.0791 million yuan, a decrease of 65.05%.
Uniwing (301166.SZ) released the third quarter report of 2024, with the company's revenue in the first three quarters reaching 8....
Shanghai Universal Biotech Co.,Ltd.'s (SZSE:301166) Shares May Have Run Too Fast Too Soon
As of the end of June, Hangzhou Antibody Research Center has developed more than 1900 SPU products.
On September 13th, Guo Longhui reported that Unilovo (301166.SZ) held a performance briefing on September 13, 2024. Regarding the question, "What new investments or collaborations does Unilovo have in product research and development?", the company stated that as of the end of June 2024, the Hangzhou Antibody R&D Center has accumulated over 1900 SPU (Standard Packaging Unit) for the research and development of products (IVD antibodies, pathological IHC antibodies, companion diagnostic antibodies, etc.). The Nanjing Protein R&D Center has accumulated over 1500 SPU for the research and development of products (drug targets, cytokines, etc.). The company's proprietary brand products have further enriched.
Shanghai Universal BiotechLtd (SZSE:301166) Is Reinvesting At Lower Rates Of ReturnNo Data
No Data
